Biotech takeover target Abivax sinks over 43% as cancer cases cloud trial data for bowel disease drug

Cnbc · Jun 02, 2026 · 625 words · By Elsa Ohlen

headphones Listen to the eFinder podcast briefing

Ready to play

Daily briefing

What to know about Biotech takeover target Abivax sinks over 43% as cancer cases cloud trial data for bowel disease drug

Shares of Abivax finished 43.6% lower on Tuesday after it reported fresh data on its lead asset, a drug for ulcerative colitis, wiping out billions in market cap and raising questions over how a potential takeover of the French biotech could unfold.

Claims checked 11

Techniques found 0

Topics 0

Coverage spectrum

Coverage gap: Low Left coverage

Left0%

Center100%

Right0%

4 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Why it matters

The medicine met its endpoints of demonstrating clinically meaningful efficacy and a placebo-adjusted remission rate of about 40% for both doses tested, but also showed that there were cancer cases among patients taking the higher dose.

Common ground

"[The] cancer signal complicates matters," a Jefferies analyst said.

Perspective signals

No major persuasion pattern has been attached yet, so the source, headline, and evidence should carry most of the weight for readers.

Follow-up questions

What concrete event or decision sits underneath the headline: Biotech takeover target Abivax sinks over 43% as cancer cases cloud trial data for bowel disease drug?
What evidence would most clearly confirm or weaken the claim that AbbVie's Rinqvoc... carries a U.S. Food and Drug Administration warning of malignancy?
What should readers watch for in the next update to know whether the story is changing?

open_in_new Read the original article: https://www.cnbc.com/2026/06/02/abivax-stock-bowel-crohns-disease-trial-data.htm…

fact_checkClaims Checked

eFinder analyzed this article and checked 11 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

check_circle Corroborated 7

verified Verified 1

verified Verified By Reference 1

schedule Pending 1

help Insufficient Evidence 1

verified

Claim 1: “AbbVie's Rinqvoc... carries a U.S. Food and Drug Administration warning of malignancy”

VERIFIED

FDA approval documentation and drug risk information explicitly state that Rinvoq may increase the risk of certain cancers, including lymphoma and skin cancers.

travel_explore

web search NEUTRAL — Oct 13, 2025 · RINVOQ may increase your risk of certain cancers. Lymphoma and other cancers, including skin cancers, can happen. Current or past smokers are at ...
https://news.abbvie.com/2025-10-13-U-S-Food-and-Drug-Adminis…

travel_explore

web search NEUTRAL — Cancer and immune system problems. RINVOQ may increase your risk of certain cancers. Lymphoma and other cancers, including skin cancers, can happen. Current or ...
https://www.rinvoq.com/side-effects

travel_explore

web search NEUTRAL — Jun 25, 2021 · AbbVie's big expansion for Rinvoq is still unable to move forward, thanks to FDA delays that spell trouble across the entire JAK inhibitor ...
https://www.fiercepharma.com/pharma/abbvie-s-big-rinvoq-ambi…

check_circle

Claim 2: “The medicine met its endpoints of demonstrating clinically meaningful efficacy and a placebo-adjusted remission rate of about 40% for both doses tested”

CORROBORATED

Multiple independent news sources confirm the placebo-adjusted remission rates were approximately 40% (specifically 39% and 40%) for both doses.

menu_book

wikipedia NEUTRAL — Obefazimod is an investigational new drug that is being evaluated for the treatment of ulcerative colitis. It is miR-124 micro RNA upregulator. Obefazimod was developed by the French biotech company …
https://en.wikipedia.org/wiki/Obefazimod

menu_book

wikipedia NEUTRAL — Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with c…
https://en.wikipedia.org/wiki/Abivax

menu_book

wikipedia NEUTRAL — Marc de Garidel is a French Biotech Entrepreneur. He is the CEO of Abivax, a French clinical-stage, publicly traded biotechnology company (ABVX at Euronext Paris and Nasdaq Global Market), which he jo…
https://en.wikipedia.org/wiki/Marc_de_Garidel

+ 3 more evidence sources

check_circle

Claim 3: “Shares of Abivax finished 43.6% lower on Tuesday”

CORROBORATED

Multiple sources report a sharp decline on Tuesday. While Benzinga mentions 35% and Investing.com mentions 40.63%, another source specifically states shares 'closed down 44% on Tuesday', which aligns closely with the claim of 43.6%.

travel_explore

web search NEUTRAL — June 2 (Reuters) - Abivax shares tumbled on Tuesday after the French biotech reported late-stage data for its experimental inflammatory bowel drug, with investors focusing on safety concerns even as t…
https://finance.yahoo.com/sectors/healthcare/articles/abivax…

travel_explore

web search NEUTRAL — Abivax shares plunge more than 35% as cancer cases reported in a Phase 3 trial overshadow strong efficacy results for ulcerative colitis drug.ABVX Stock Price Activity: Abivax shares were down 35.25% …
https://www.benzinga.com/news/health-care/26/06/52935406/why…

travel_explore

web search NEUTRAL — Investing.com -- Abivax shares fell sharply on Tuesday after its experimental ulcerative colitis pill posted...The pre-market share volume is 2,580,000.00, and the stock has decreased by -52.69, or -4…
https://www.investing.com/equities/abivax-adr

check_circle

Claim 4: “There were also four cases of skin cancer on the higher 50 mg dose”

CORROBORATED

Two independent sources confirm four cases of non-melanoma skin cancer in the higher-dose (50 mg) group.

travel_explore

web search NEUTRAL — Four cases of non-melanoma skin cancer in the higher-dose group. Abivax stated that investigators found no evidence linking the prostate, breast, or colon cases directly to treatment.
https://globalhealthcaremagazine.com/news/abivax-bowel-disea…

travel_explore

web search NEUTRAL — 58 (roughly 2.35%) cases of new-onset diabetes.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6…

travel_explore

web search NEUTRAL — Shares of ABVX closed down 44% on Tuesday, clocking its worst day ever, on reports of a number of non-melanoma skin cancers and other malignancies observed in its ulcerative colitis trial. In this pho…
https://stocktwits.com/news-articles/markets/equity/abvx-sto…

verified

Claim 5: “Abivax [is] led by CEO Marc de Garidel”

VERIFIED BY REFERENCE

Wikipedia explicitly identifies Marc de Garidel as the CEO of Abivax.

check_circle

Claim 6: “In the study cohort, there was one reported case each of prostate cancer, breast cancer, and colonic dysplasia”

CORROBORATED

Multiple sources explicitly list one case each of prostate cancer, breast cancer, and colonic dysplasia in the study cohort.

travel_explore

web search NEUTRAL — Jun 2, 2026 ... The malignancies other than non-melanoma skin cancer (NMSC) in the 50-mg cohort were identified as one prostate (which was disclosed during the ...
https://www.bioworld.com/articles/731525-cancer-specter-loom…

travel_explore

web search NEUTRAL — Jun 2, 2026 ... In the study cohort, there was one reported case each of prostate cancer, breast cancer, and colonic dysplasia, which Abivax said were ...
https://www.cnbc.com/2026/06/02/abivax-stock-bowel-crohns-di…

travel_explore

web search NEUTRAL — Jun 2, 2026 ... Abivax emphasized that trial investigators considered the prostate, breast, and colonic malignancies unrelated to treatment and noted the ...
https://european-biotechnology.com/latest-news/abivax-delive…

check_circle

Claim 7: “The Paris-listed stock gained nearly 1,700% in 2025”

CORROBORATED

Three independent sources (CNBC, a market analysis site, and a Facebook news post) all report the stock rose nearly 1,700% in 2025.

menu_book

+ 3 more evidence sources

schedule

Claim 8: “The company on Monday reiterated the expectation to submit obefazimod for FDA approval in the fourth quarter and a potential launch in 2027”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

check_circle

Claim 9: “The trial results... were from a maintenance study in which Abivax assessed the effect of the drug, obefazimod, over 44 weeks”

CORROBORATED

Multiple sources confirm the maintenance study for obefazimod lasted 44 weeks.

menu_book

+ 3 more evidence sources

help

Claim 10: “Rinqvoc... generated $8.3 billion in sales in 2025”

INSUFFICIENT EVIDENCE

No evidence was found in the provided search results regarding the specific sales figure of $8.3 billion for Rinvoq in 2025.

check_circle

Claim 11: “Abivax is also testing the medicine for Crohn's disease”

CORROBORATED

The official Abivax website and a clinical trial listing (NCT06456593) both confirm obefazimod is being tested for Crohn's disease.

travel_explore

web search NEUTRAL — Obefazimod is an oral small-molecule drug candidate in clinical development for the treatment of moderately to severely active ulcerative colitis (UC)
https://www.abivax.com/pipeline/abx464-for-crohns-disease/

travel_explore

web search NEUTRAL — ... Crohn's disease (CD). Intervention/Treatment, Drug : Obefazimod. Obefazimod is ... Abivax S.A.. Crohn Disease. Additional Relevant MeSH Terms. Inflammatory Bowel ...
https://clinicaltrials.gov/study/NCT06456593

travel_explore

web search NEUTRAL — Obefazimod is an investigational, orally administered, once-daily therapy and the lead drug candidate from Abivax.
https://www.abivax.com/science/obefazimod/

info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.